Multiple myeloma: genes and variants
Explore variant evidence for Multiple myeloma across 27 analyzed proteins (CRBN, BRAF, CCND1, CD3D, CD3E and 22 more). Linked ClinVar records include 10 pathogenic or likely pathogenic variants, 0 variants of uncertain significance and 0 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Multiple myeloma
CRBN: Protein cereblon
It determines substrate recognition for the CRL4-CRBN ubiquitin ligase and thereby controls degradation of selected cellular proteins. Thalidomide and related drugs bind CRBN and redirect the ligase toward new substrates, a mechanism central to their therapeutic and teratogenic effects.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CRBN have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
BRAF: Serine/threonine-protein kinase B-raf
It relays activated RAS signals through MEK and ERK to control proliferation, differentiation, and survival. Activating variants, especially V600E, drive melanoma and several other cancers and create sensitivity to pathway-directed therapies.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in BRAF have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
CCND1: G1/S-specific cyclin-D1
It partners with CDK4 and CDK6 to phosphorylate RB-family proteins and promote progression through the G1 phase of the cell cycle. Amplification, translocation, or overexpression drives many cancers, including mantle-cell lymphoma and subsets of breast cancer.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CCND1 have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
CD3D: T-cell surface glycoprotein CD3 delta chain
Within the T-cell receptor complex, it transmits antigen-recognition signals into developing and mature T cells. Biallelic loss-of-function variants can cause severe combined immunodeficiency or related T-cell immunodeficiency.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CD3D have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
CD3E: T-cell surface glycoprotein CD3 epsilon chain
It helps assemble the T-cell receptor complex and transduces antigen-recognition signals through its cytoplasmic signaling motifs. Biallelic pathogenic variants can impair T-cell development and cause severe combined immunodeficiency.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CD3E have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
CXCR4: C-X-C chemokine receptor type 4
It directs cell migration toward CXCL12 and is crucial for hematopoietic-cell homing, immune trafficking, and development. Gain-of-function variants that impair receptor desensitization cause WHIM syndrome, while tumor cells can exploit the pathway for survival and metastasis.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CXCR4 have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
IFNAR1: Interferon alpha/beta receptor 1
Together with IFNAR2, it detects type I interferons and activates JAK-STAT antiviral and immunoregulatory programs. Loss-of-function can impair antiviral defense, while excessive pathway activation contributes to interferon-driven inflammatory disease.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in IFNAR1 have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
IFNAR2: Interferon alpha/beta receptor 2
It provides the high-affinity ligand-binding component of the type I interferon receptor complex and triggers antiviral JAK-STAT signaling with IFNAR1. Biallelic loss-of-function variants can predispose to severe viral infections, including critical COVID-19 in some individuals.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in IFNAR2 have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
IRF4: Interferon regulatory factor 4
It controls differentiation and function of B cells, plasma cells, T cells, and other immune lineages in a context-dependent manner. Germline variants can cause immunodeficiency, while rearrangements or abnormal expression drive several lymphoid malignancies.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in IRF4 have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
KRAS: GTPase KRas
A small GTPase that acts as a molecular switch in the RAS-MAPK signaling pathway. By cycling between GDP- and GTP-bound states, it relays growth and survival signals, and activating KRAS variants are common drivers of cancer.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in KRAS have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
MAX: Protein max
It forms DNA-binding dimers with MYC-family proteins and other partners, balancing transcriptional programs that promote or restrain proliferation. Germline loss-of-function variants predispose to pheochromocytoma and paraganglioma, while altered MAX-MYC signaling is central to many cancers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MAX have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
NR3C1: Glucocorticoid receptor
It converts glucocorticoid binding into transcriptional programs that regulate metabolism, stress responses, inflammation, and immune activity. Loss-of-function variants can cause glucocorticoid resistance, while excessive or prolonged signaling underlies many adverse effects of corticosteroid therapy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in NR3C1 have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
NRAS: GTPase NRas
Its active GTP-bound state drives RAF-MEK-ERK and PI3K signaling downstream of growth-factor receptors. Somatic activating variants are common drivers of melanoma, leukemia, and other cancers, while germline activating variants can cause Noonan syndrome.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in NRAS have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
TNFRSF13B: Tumor necrosis factor receptor superfamily member 13B
It responds to BAFF and APRIL and regulates B-cell survival, antibody production, and immunoglobulin class switching. Pathogenic variants are enriched in common variable immunodeficiency and can contribute to antibody deficiency, although penetrance is incomplete for many heterozygous alleles.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TNFRSF13B have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
TOP2A: DNA topoisomerase 2-alpha
It resolves DNA tangles and supercoils by passing one double helix through a transient double-strand break in another, a process essential during replication and chromosome segregation. It is the target of widely used anticancer drugs including anthracyclines and etoposide.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TOP2A have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
TP53: Cellular tumor antigen p53
It coordinates transcriptional responses to DNA damage and other cellular stresses, promoting cell-cycle arrest, senescence, DNA repair, or apoptosis when appropriate. Loss of this tumor-suppressive control is one of the most common events in cancer, while germline pathogenic variants cause Li-Fraumeni syndrome.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TP53 have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
TUBA1A: Tubulin alpha-1A chain
An alpha-tubulin chain that pairs with beta-tubulin to build microtubules. Microtubules provide tracks for transport and help shape dividing and migrating cells, making TUBA1A especially important for fetal brain development.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TUBA1A have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
TUBB2B: Tubulin beta-2B chain
It contributes to neuronal microtubules needed for progenitor division, neuronal migration, axon development, and cortical organization. Heterozygous pathogenic variants cause tubulinopathy with polymicrogyria, cortical dysplasia, developmental delay, and sometimes epilepsy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TUBB2B have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
TUBB3: Tubulin beta-3 chain
It forms neuronal microtubules required for axon growth, guidance, and intracellular transport. Heterozygous pathogenic variants can cause congenital fibrosis of the extraocular muscles type 3 and broader tubulinopathy phenotypes with brain and cranial-nerve abnormalities.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TUBB3 have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
KMT2C: Histone-lysine N-methyltransferase 2C
It helps establish enhancer-associated H3K4 methylation and thereby controls lineage-specific transcription together with other COMPASS-family proteins. Somatic loss-of-function alterations are frequent across cancers, while germline variants can cause neurodevelopmental phenotypes.
2 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in KMT2C have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
AURKA: Aurora kinase A
It coordinates centrosome maturation, spindle assembly, and chromosome segregation during mitosis. Overexpression or amplification can promote chromosomal instability and tumor progression, making its kinase activity a target of anticancer drug development.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in AURKA have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
DNMT3A: DNA (cytosine-5)-methyltransferase 3A
It establishes new DNA methylation patterns during development and hematopoietic differentiation. Somatic variants are common in clonal hematopoiesis and acute myeloid leukemia, while germline variants cause Tatton-Brown-Rahman overgrowth syndrome.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in DNMT3A have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
FAT1: Protocadherin Fat 1
A large cell-surface cadherin involved in cell polarity, cell-cell contact, and directed cell migration. These functions help organize developing and renewing tissues.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FAT1 have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
FLT3: Receptor-type tyrosine-protein kinase FLT3
Its signaling supports survival and expansion of early hematopoietic progenitors. Internal tandem duplications and kinase-domain mutations produce constitutive activity in acute myeloid leukemia and are important prognostic markers and therapeutic targets.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FLT3 have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
NKX2-1: Homeobox protein Nkx-2.1
It controls developmental and tissue-specific gene programs in lung, thyroid, and basal ganglia. Haploinsufficiency causes brain-lung-thyroid syndrome, variably combining chorea or developmental movement disorder, neonatal respiratory disease, and thyroid dysfunction.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in NKX2-1 have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
PIK3R2: Phosphatidylinositol 3-kinase regulatory subunit beta
The p85β regulatory subunit of class IA phosphoinositide 3-kinase, which helps control PI3K–AKT signaling and cell growth. Specific activating variants cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PIK3R2 have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
YAP1: Transcriptional coactivator YAP1
When Hippo signaling permits nuclear accumulation, it integrates mechanical, polarity, and growth cues to control proliferation, survival, and organ size. Persistent nuclear YAP activity contributes to many cancers, while germline loss-of-function variants can cause developmental eye abnormalities.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in YAP1 have source records linked to Multiple myeloma. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Multiple myeloma
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| FLT3 Y572H | 572 | Cytoplasmic | Pathogenic / likely pathogenic |
| AURKA F346L | 346 | Protein kinase | Pathogenic / likely pathogenic |
| KMT2C L3046P | 3046 | Pathogenic / likely pathogenic | |
| CRBN N367I | 367 | CULT | Pathogenic / likely pathogenic |
| KMT2C Q3061E | 3061 | Coiled coil | Pathogenic / likely pathogenic |
| YAP1 S163C | 163 | Pathogenic / likely pathogenic | |
| DNMT3A A3S | 3 | Pathogenic / likely pathogenic | |
| FAT1 M240I | 240 | Cadherin 2 | Pathogenic / likely pathogenic |
| PIK3R2 V284M | 284 | Rho-GAP | Pathogenic / likely pathogenic |
| NKX2-1 A116T | 116 | Pathogenic / likely pathogenic |
Which prediction tools work for Multiple myeloma
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 76 out of 100
- PolyPhen-2: 67 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 66 out of 100
- SIFT: 63 out of 100
- MutPred: 63 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 62 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 54 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 51 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Tatton-Brown-Rahman overgrowth syndrome also has ClinVar records linked to DNMT3A variants; they fall mostly in different places as the Multiple myeloma variants (32 pathogenic / likely pathogenic).
- Heyn-Sproul-Jackson syndrome also has ClinVar records linked to DNMT3A variants; they fall mostly in different places as the Multiple myeloma variants (5 pathogenic / likely pathogenic).
- Acute myeloid leukemia also has ClinVar records linked to DNMT3A variants; they fall mostly in different places as the Multiple myeloma variants (5 pathogenic / likely pathogenic).
- Nephrotic syndrome also has ClinVar records linked to FAT1 variants; they fall mostly in different places as the Multiple myeloma variants (4 pathogenic / likely pathogenic).
- Acute myeloid leukemia also has ClinVar records linked to FLT3 variants; they fall mostly in different places as the Multiple myeloma variants (7 pathogenic / likely pathogenic).
Diseases related to Multiple myeloma
- Acute myeloid leukemia, also linked to DNMT3A, FLT3, KRAS, NRAS and 2 more
- Non-small cell lung carcinoma, also linked to BRAF, KRAS, TUBA1A, TUBB2B and 1 more
- Prostate cancer, also linked to NR3C1, TOP2A, TUBA1A, TUBB2B and 1 more
- Melanoma, also linked to BRAF, IFNAR1, IFNAR2, IRF4 and 1 more
- Colorectal cancer, also linked to BRAF, KRAS, NRAS and TP53
- RASopathy, also linked to BRAF, KRAS and NRAS
- Noonan syndrome, also linked to BRAF, KRAS and NRAS
- Noonan syndrome and Noonan-related syndrome, also linked to BRAF, KRAS and NRAS
- Cardiofaciocutaneous syndrome, also linked to BRAF, KRAS and NRAS
- Ovarian cancer, also linked to TOP2A, TUBB2B and TUBB3
- Gastric cancer, also linked to KRAS, TP53 and TUBA1A
- Urinary bladder cancer, also linked to KMT2C, KRAS and TP53
Frequently asked questions
Which genes have records linked to Multiple myeloma?
This view contains 27 analyzed proteins: CRBN, BRAF, CCND1, CD3D, CD3E and 22 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 10 pathogenic or likely pathogenic variants, 0 variants of uncertain significance and 0 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 10 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center